Abstract
Specific inactivation of gene expression is an attractive approach for rational drug design to combat degenerative diseases and infectious agents. Oligonucleotide-directed triple-helix formation at cis-acting elements of gene promoters, short oligonucleotides containing base sequences that are complementary to the messenger RNA (antisense oligos), and RNA enzymes (ribozymes) that specifically cleave messenger RNA molecules are currently being used both as experimental tools and as therapeutic agents. Mechanisms of action of various oligonucleotide-based drugs, recent developments in the drug-delivery approaches, and future potentials are discussed in this review.
Original language | English (US) |
---|---|
Pages (from-to) | 11-22 |
Number of pages | 12 |
Journal | Biochemical and Molecular Medicine |
Volume | 62 |
Issue number | 1 |
DOIs | |
State | Published - Oct 1997 |
ASJC Scopus subject areas
- Biochemistry